Clinical Evidence in Respiratory and Urinary Tract Infections: Focus on Ceftibuten
Abstract
Background: Antimicrobial resistance (AMR) is one of the most pressing global health problems, resulting from the misuse and overuse of antibiotics across various sectors, which has led to the emergence and spread of resistant microorganisms. AMR occurs when microorganisms no longer respond to antibiotics. In Italy alone, AMR is responsible for over 10,000 deaths each year, exceeding 40% of all AMR, attributable deaths in the EU/EEA. This alarming trend highlights the urgent need to preserve effective treatment options and to re-evaluate the role of well-established oral antibiotics with a favourable pharmacological and microbiological profile.
Summary: Ceftibuten is an oral third-generation cephalosporin with potent activity against many Gram-negative and some Gram-positive pathogens, including several Gram-negative pathogens. It is approved for the treatment of respiratory and urinary tract infections (UTIs), both uncomplicated and complicated, in adults as well as in children. This review discusses clinical and pharmacological data supporting ceftibuten's efficacy, safety, pharmacokinetics, and microbiological spectrum. Moreover, the paper discusses its potential role in contemporary clinical practice, especially considering recent supply interruptions and increasing resistance patterns.
Key messages: Ceftibuten represents an oral treatment option for respiratory and UTIs, particularly where resistance to other agents limits therapeutic choices. Its favourable…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.